MMWR. Morbidity and mortality weekly report · 2022
Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Malenfant Jason H, Joyce Allison, Choi Mary J, Cossaboom Caitlin M, Whitesell Amy N, Harcourt Brian H, Atmar Robert L, Villanueva Julie M, Bell Beth P, Hahn Christine, Loehr Jamie, Davey Richard T, Sprecher Armand, Kraft Colleen S, Shoemaker Trevor, Montgomery Joel M, Helfand Rita, Damon Inger K, Frey Sharon E, Chen Wilbur H
Аннотация
On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).